Table 2. Phenotypic analysis of PBLs... | American Society of Hematology

Table 2.

Phenotypic analysis of PBLs from LDGL patients

Patient no.	CD16⁺ CD3^- cells, %	KIR2DL1 KIR2DS1 (EB6b)	KIR2DL2/3 KIR2DS2 (GL183)	KIR2DS4 (FES172)	KIR3DL1 KIR3DS1 (Z27)	KIR3DL2 (Q66)	CD94 (XA185)	NKG2-A (Z199)	LIR-1 (F278)
1*	82	1	81†	0	2	1	85	87	55
2*	51	51†	8	13	3	3	77	9	45
3*	64	1	1	65†	1	0	67	66	31
4*	75	0	75†	0	0	27	76	75	62
5	71	1	73†	0	0	0	79	75	45
6	48	5	48†	0	0	7	62	4	35
7	40	0	39†	1	1	0	45	42	29
8	35	0	31†	1	0	0	39	34	34
9*	34	25	17	0	4	12	35	31	29
10*	62	29	15	0	3	4	33	35	32
11	50	25	8	6	5	0	38	35	49
12	46	8	23	0	10	2	45	48	35
13	70	12	6	21	0	0	74	73	77
14	59	0	0	25	1	10	42	40	37
15*	73	3	6	0	2	1	75	73	68
16	41	0	0	1	0	0	48	44	31
17	71	0	2	9	0	0	78	73	52
18	67	1	3	1	1	3	69	68	42
CTR1	14	6	7	8	7	4	20	12	12
CTR2	16	9	9	0	1	4	21	4	4

Patient no.	CD16⁺ CD3^- cells, %	KIR2DL1 KIR2DS1 (EB6b)	KIR2DL2/3 KIR2DS2 (GL183)	KIR2DS4 (FES172)	KIR3DL1 KIR3DS1 (Z27)	KIR3DL2 (Q66)	CD94 (XA185)	NKG2-A (Z199)	LIR-1 (F278)
1*	82	1	81†	0	2	1	85	87	55
2*	51	51†	8	13	3	3	77	9	45
3*	64	1	1	65†	1	0	67	66	31
4*	75	0	75†	0	0	27	76	75	62
5	71	1	73†	0	0	0	79	75	45
6	48	5	48†	0	0	7	62	4	35
7	40	0	39†	1	1	0	45	42	29
8	35	0	31†	1	0	0	39	34	34
9*	34	25	17	0	4	12	35	31	29
10*	62	29	15	0	3	4	33	35	32
11	50	25	8	6	5	0	38	35	49
12	46	8	23	0	10	2	45	48	35
13	70	12	6	21	0	0	74	73	77
14	59	0	0	25	1	10	42	40	37
15*	73	3	6	0	2	1	75	73	68
16	41	0	0	1	0	0	48	44	31
17	71	0	2	9	0	0	78	73	52
18	67	1	3	1	1	3	69	68	42
CTR1	14	6	7	8	7	4	20	12	12
CTR2	16	9	9	0	1	4	21	4	4

Surface expression of the various receptors was evaluated by FACS analysis using the mAbs indicated in parentheses. Values indicate percentage of positive cells.

The 7 patients from whom it was possible to derive a polyclonal NKLGL line.

†

Values in which the percent of NK cells stained by a given anti-KIR mAb approximated that of CD16⁺CD3^- cells.

View Large

This Feature Is Available To Subscribers Only